Immunostimulant- Adjuvant Therapy For Influenza A (H1N1)

Construction of Influenza A/H1N1 Virosomal Nanobioparticles

Background and Aims: Influenza is one of the main respiratory infections of humans, responsible for 300,000–500,000 annual deaths world-wide. Vaccination is one of the best ways to prevent infections including influenza. Influenza virosomes are virus-like particles, which retain the cell binding and membrane fusion properties of the native virus, but lack the ribonucleoprotein (RNP). A vi...

Glucan-immunostimulant, adjuvant, potential drug.

β-glucans belong to a group of biologically active natural compounds called biological response modifiers. These substances represent highly conserved structural components of cell walls in fungi, yeast, grain and seaweed. Despite almost 160 years of intensive research, the exact mechanisms of their action remain unsolved. The significant role of glucans in cancer treatment, infection immunity,...

2009 H1N1 Influenza Virus Seroepidemiology

Preparing for 2009 H1N1 Influenza.

In 1743, when disease was presumed to be astral in origin, European newspapers reported on a contagious influence (inf luenza in Italian) that was being visited on the citizens of Rome. Two hundred years later, Wilson Smith and colleagues would isolate an influenza A virus, one of the members of the orthomyxovirus family.1 The key reservoirs of all influenza A viruses are migrating waterfowl, a...

Influenza A (H1N1)-associated pneumonia.

OBJECTIVE To describe the characteristics of patients with influenza A (H1N1)-associated pneumonia treated at two hospitals in the region of Liguria, Italy, as well as to describe their treatment and outcomes. METHODS This was a prospective observational study including all patients older than 16 years of age with a confirmed diagnosis of influenza A (H1N1) who were admitted to Villa Scassi H...